SG11202003965VA - Il-2 muteins and uses thereof - Google Patents

Il-2 muteins and uses thereof

Info

Publication number
SG11202003965VA
SG11202003965VA SG11202003965VA SG11202003965VA SG11202003965VA SG 11202003965V A SG11202003965V A SG 11202003965VA SG 11202003965V A SG11202003965V A SG 11202003965VA SG 11202003965V A SG11202003965V A SG 11202003965VA SG 11202003965V A SG11202003965V A SG 11202003965VA
Authority
SG
Singapore
Prior art keywords
muteins
Prior art date
Application number
SG11202003965VA
Other languages
English (en)
Inventor
Nathan Higginson-Scott
Joanne L Viney
Jyothsna Visweswaraiah
Erik Robert Sampson
Kevin Lewis Otipoby
Original Assignee
Pandion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/109,897 external-priority patent/US10174092B1/en
Application filed by Pandion Therapeutics Inc filed Critical Pandion Therapeutics Inc
Publication of SG11202003965VA publication Critical patent/SG11202003965VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SG11202003965VA 2017-12-06 2018-11-28 Il-2 muteins and uses thereof SG11202003965VA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762595357P 2017-12-06 2017-12-06
US201862675972P 2018-05-24 2018-05-24
US201862721644P 2018-08-23 2018-08-23
US16/109,897 US10174092B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
US16/109,875 US10174091B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
PCT/US2018/062808 WO2019112854A1 (en) 2017-12-06 2018-11-28 Il-2 muteins and uses thereof

Publications (1)

Publication Number Publication Date
SG11202003965VA true SG11202003965VA (en) 2020-06-29

Family

ID=66751187

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003965VA SG11202003965VA (en) 2017-12-06 2018-11-28 Il-2 muteins and uses thereof

Country Status (11)

Country Link
EP (1) EP3720470A4 (ja)
JP (1) JP7250790B2 (ja)
KR (2) KR20200097275A (ja)
CN (1) CN111432831A (ja)
AU (1) AU2018378078A1 (ja)
BR (1) BR112020011343A2 (ja)
CA (1) CA3083941A1 (ja)
IL (1) IL274844A (ja)
MX (1) MX2020005208A (ja)
SG (1) SG11202003965VA (ja)
WO (1) WO2019112854A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
WO2021034890A1 (en) * 2019-08-19 2021-02-25 Pandion Therapeutics, Inc. Targeted immunotolerance with a pd-1 agonist
CN110642934B (zh) * 2019-09-10 2022-08-23 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
WO2021076805A1 (en) 2019-10-15 2021-04-22 Moderna TX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
CN112358540A (zh) * 2020-11-03 2021-02-12 安徽环球基因科技有限公司 一种重组il2在毕赤酵母中的生产方法
TW202345889A (zh) * 2022-03-03 2023-12-01 大陸商海南先聲藥業有限公司 ＩＬ２突變體－抗體Ｆｃ嵌段融合蛋白的藥物組合物及其應用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1007907B (zh) * 1985-04-30 1990-05-09 弗·哈夫曼-拉罗彻有限公司 重组人类白细胞介素-2的提纯
WO2005007121A2 (en) * 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US9428567B2 (en) * 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
US20140170153A1 (en) * 2011-05-31 2014-06-19 Novo Nordisk A/S Il-21 epitope and il-21 ligands
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
SG10202010158TA (en) * 2014-07-21 2020-11-27 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20180133198A (ko) * 2016-05-04 2018-12-13 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
WO2018184965A1 (en) * 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
CA3064435A1 (en) * 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
WO2019112852A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance

Also Published As

Publication number Publication date
WO2019112854A1 (en) 2019-06-13
EP3720470A4 (en) 2021-09-15
CN111432831A (zh) 2020-07-17
AU2018378078A1 (en) 2020-06-18
JP2021507690A (ja) 2021-02-25
BR112020011343A2 (pt) 2020-11-17
MX2020005208A (es) 2020-08-20
KR20200097275A (ko) 2020-08-18
KR20240039201A (ko) 2024-03-26
IL274844A (en) 2020-07-30
EP3720470A1 (en) 2020-10-14
CA3083941A1 (en) 2019-06-13
JP7250790B2 (ja) 2023-04-03

Similar Documents

Publication Publication Date Title
IL274844A (en) IL-2 mutants and their uses
ZA202002191B (en) Adenovirus and uses thereof
ZA202002184B (en) Adenovirus and uses thereof
IL271275A (en) Preparations containing coronas and their uses
IL293377A (en) hsd17b13 variants and their uses
EP4076448A4 (en) FLUOROALKYLATED OXADIAZOLES AND THEIR USES
RS64556B1 (sr) Novi polipeptidi i njihova upotreba u medicini
RS59895B1 (sr) Modularna i podesiva klizna podloga
IL274220A (en) Adenovirus and its uses
SG11202008543RA (en) Pyrrolidineamide derivatives and uses thereof
ZA202005144B (en) Parenteral formulations and uses thereof
IL274953A (en) Unit operation and its use
SG11202002224XA (en) Composition and uses thereof
IL275211A (en) Fast and flexible segment chains - division
IL273671A (en) Cornoline variants and their use
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
IL280369A (en) New myokines and uses thereof
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
IL261670B (en) Magnesium-containing formulation and uses thereof
IL287503A (en) Thio-semicarbazide compounds and their use
GB201816605D0 (en) New formulations and uses thereof
GB201716745D0 (en) New formulations and uses thereof
GB201815546D0 (en) Composition and uses thereof
GB201812952D0 (en) Compositions and uses thereof
GB201805096D0 (en) Composition and uses thereof